FRONTEO Healthcare, Inc. (“FRONTEO Healthcare”), a subsidiary of
FRONTEO, Inc. (“FRONTEO”) (NASDAQ:FTEO) (TSE:2158) that provides
medical data analysis solutions using the artificial intelligence
(“AI”) engine “KIBIT” and Japanese Foundation for Cancer Research
(“JFCR”) have begun research and development of Cancer Precision
Medicine System that may utilize cutting-edge genome analysis
technology and AI. Through this research, FRONTEO Healthcare and
JFCR aim to develop a cancer precision medicine that will provide
the best treatment for each cancer patient based on genetic tests.
JFCR established the Cancer Precision Medicine
Center in October 2016. Employing cutting-edge technologies for
genome analysis on cancer cells and tissues, it aims to develop
next-generation cancer diagnostics that may result in best
treatments. FRONTEO Healthcare also announced in October 2016 that
it had begun the development of its Cancer Precision Medicine AI
System (“CPM-AI System.”)
Through their joint research activity, JFCR and
FRONTEO Healthcare will seek to develop a system that supports
physicians in making clinical decisions based on genetic
information of cancer cells. The system will consist of AI that
searches for academic papers which could support to find the most
appropriate treatment in each individual based on the result of
genetic test.
The Cancer Precision Medicine Center will seek
to develop a system that integrates and analyzes information
pertaining to cancer patients, such as cancer genome data, by
employing the latest methods including clinical sequencing, which
conducts a comprehensive search of genetic mutation in cancer
cells, and liquid biopsy, which detects genetic mutations in the
blood and other bodily fluids. One of the CPM-AI system that
FRONTEO Healthcare will develop through “Diagnosis Support System”
is a system that analyzes academic papers and medical data
employing the knowledge of cancer experts from every field. The
system will make suggestions when physicians decide on the course
of treatment based on test results.
In addition to the Diagnosis Support System,
FRONTEO Healthcare will develop an “Informed Consent (IC) Support
System,” in which FRONTEO’s AI technology will maximize an
efficiency of IC by supplementing explanations according to the
degree of understanding the patients and their families. FRONTEO
Healthcare plans to complete the development of the Diagnosis
Support System and the Informed Consent Support System at the end
of 2021.
Overview of CPM-AI System
Development
An infographic accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/83f73696-a87e-4bc4-aebe-8bc216687967
AI “KIBIT” presents a selected range of
academic papers by acquiring the knowledge of experts in specific
fields
Currently, one challenge in advancing cancer
precision medicine is that as the number of medical studies and
academic reports released increases, the available options are
expanding for patients’ genetic information or abnormal conditions
occurring in cancer cells, treatment regimens, and choices of
medications with lower incidence of adverse events.
There are high expectations for a system that
can share information among physicians in a shorter period of time
through the use of AI to identify papers with findings related to
treatment methods and the most appropriate drugs. FRONTEO
Healthcare’s CPM-AI System can identify papers with the same
elements that experts have confirmed as indicating high quality,
and can exclude those papers with the factors that experts have
identified as indicating low quality. In many cases, a search for
scientifically high quality papers is important for the development
of cancer precision medicine. For example, whether only
papers describing results of monotherapy should be analyzed or
those from combination therapy can be also included, and/or whether
genetic information for the analysis should be obtained from cancer
cells or those from normal cells should be analyzed. These elements
should be important when searching for papers. It has been
confirmed that if KIBIT is trained in whether or not each of these
aspects of research is required, it is able to extract the papers
that meet its objectives.
After learning from the most recent medical
information selected by experts in a specific field as training
data and preselecting the search subjects, KIBIT can function as a
filter that reduces unnecessary data and noises. When the CPM-AI
system is developed, it is expected that physicians who are in
daily contact with cancer patients will be able to make use of the
knowledge of specialists in every field.
JFCR has investigated various technologies,
including AI developed in Japan, to find a solution that can
comprehend the unique genetic information of Japanese people and
protect personal medical data. KIBIT has achieved results for its
depth of learning and obtaining effective results in a short period
of time with a small amount of data. This, in addition to its
cost-effectiveness and the short time to introduction, were highly
valued and made the joint research possible.
By developing and providing a system that
leverages the respective specialties and strengths of JFCR and
FRONTEO Healthcare, the organizations are striving to reduce
Japan’s cancer death rate, help to prevent recurrence, and decrease
the appropriate allocation of healthcare spending.
About FRONTEO, Inc.FRONTEO, Inc.
(“FRONTEO”) (Nasdaq:FTEO) (TSE:2158) supports the analysis of big
data based on behavior informatics by utilizing its technology,
"KIBIT". FRONTEO's KIBIT technology is driven by FRONTEO artificial
intelligence based on knowledge acquired through its litigation
support services. KIBIT incorporates experts' tacit knowledge,
including their experiences and intuitions, and utilizes that
knowledge for big data analysis. FRONTEO continues to expand its
business operations by applying KIBIT to new fields such as
healthcare and marketing. FRONTEO was founded in 2003 as a provider
of e-discovery and international litigation support services. These
services include the preservation, investigation and analysis of
evidence materials contained in electronic data, and computer
forensic investigation. FRONTEO provides e-discovery and litigation
support by making full use of its data analysis platform, "Lit i
View", and its Predictive Coding technology adapted to Asian
languages. The company name was changed from UBIC, Inc. to FRONTEO,
Inc. as of July 1, 2016.
For more information about FRONTEO, contact
global_pr@fronteo.com or visit http://www.fronteo.com/global/.
About Japanese Foundation for Cancer
Research
- Foundation name: Japanese Foundation for Cancer Research
- Date of Establishment: April 1908
- Representative: Takao Kusakari, Chairman
- Purpose of Establishment: Development of revolutionary cancer
treatments and preventative methods through systemic cancer
research and promotion of advanced therapies, and their diffusion
through our operations in training personnel, international
exchange, and survey research. By doing so, we will contribute to
the welfare of all mankind by overcoming cancer.
- Main Organizations: The Cancer Institute Hospital of JFCR,
Cancer Institute, Cancer Chemotherapy Center, Cancer Precision
Medicine CenterURL: http://www.jfcr.or.jp/english/
Safe Harbor StatementThis
announcement contains forward-looking statements. These
forward-looking statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements can be identified by terminology such as
"will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates" and similar statements. Among other things,
the amount of data that FRONTEO expects to manage this year and the
potential uses for FRONTEO's new service in intellectual
property-related litigation, contain forward-looking statements.
FRONTEO may also make written or oral forward-looking statements in
its reports filed with, or furnished to, the U.S. Securities and
Exchange Commission, in its annual reports to shareholders, in
press releases and other written materials and in oral statements
made by its officers, directors or employees to third parties.
Statements that are not historical facts, including statements
about FRONTEO's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and
uncertainties. A number of factors could cause actual results to
differ materially from those contained in any forward-looking
statement, including but not limited to the following: FRONTEO's
goals and strategies; FRONTEO's expansion plans; the expected
growth of the data center services market; expectations regarding
demand for, and market acceptance of, FRONTEO's services; FRONTEO's
expectations regarding keeping and strengthening its relationships
with customers; FRONTEO's plans to invest in research and
development to enhance its solution and service offerings; and
general economic and business conditions in the regions where
FRONTEO provides solutions and services. Further information
regarding these and other risks is included in FRONTEO's reports
filed with, or furnished to the Securities and Exchange Commission.
FRONTEO does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
All information provided in this press release and in the
attachments is as of the date of this press release, and FRONTEO
undertakes no duty to update such information, except as required
under applicable law.
CONTACT: FRONTEO Global PR
global_pr@fronteo.com
Grafico Azioni FRONTEO (NASDAQ:FTEO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni FRONTEO (NASDAQ:FTEO)
Storico
Da Giu 2023 a Giu 2024